Cannabinoid Biosciences is a biopharmaceutical company that intends to research, develop, and commercialize treatments derived from cannabinoids. It plans to raise $125 million through private placements to fund the acquisition of 10 profitable cannabis dispensaries and cultivation facilities which it will consolidate and take public on a major stock exchange, aiming to provide investors exposure to the ground floor of the cannabis industry. The company projects the rollup could be worth over $4.6 billion once public based on industry multiples.

1. A California Based
Biopharmaceutical
Company
Www.CBDXFUND.COM
This Cannabinoid Biosciences presentation contains
certain forward-looking statements that are subject to
known and unknown risks and uncertainties that
could cause actual results to differ materially from
those expressed or implied by such statements.
Such risks and uncertainties include, but are not
limited to the Risk Factors noted in the Company’s
filings with the Securities and Exchange Commission.
The Company undertakes no obligations to update
any forward-looking statements, whether as a result
of new information, future events or otherwise.

2. About Us
Company Introduction
Cannabinoid Biosciences, Inc. (“CBDZ”) is a biopharmaceutical
company, which intends to engage in the discovery, development and
commercialization of cures and novel therapeutics derived from:
• Proprietary Cannabinoid
• Cannabidiol, Endocannabinoids
• Phytocannabinoids
• Synthetic Cannabinoids product platform suitable for specific
treatments in a broad range of disease areas.
Www.CBDXFUND.COM

3. 3
Biopharmaceutical R&D and
commercialization of cures
and novel therapeutics from
cannabinoids product
formulations for broad
range of disease areas.
RESEARCH & DEVELOPMENT
Our Business
Details about our business
INVESTMENTS & CONSOLIDATION
Investments into legal-
cannabis businesses and
deriving value from
rollup/consolidation events
that leads to IPO in US or
Canada
FINANCIAL PRODUCTS
Financial products in form of
asset-backed loans, business
property mortgages and other
financial products to qualified
individuals/businesses in the
legal-cannabis businesses
Services include top-level financial
reporting, Accounting, SEC Reporting,
Business Valuation, Mergers &
Acquisitions, GAAP/ IFRS Conversion,
IPO/RTO Prep, Section 280E Tax, and
Biological Assets Valuation to legal-
cannabis businesses.
PROFESSIONAL SERVICES
Www.CBDXFUND.COM

4. 4
Our Market
Market Opportunity
As of November 30, 2018, Thirty-three states and the District
of Columbia currently have passed laws and/or regulations
that recognize, in one form or another, legitimate medical
uses for cannabis and consumer use of cannabis in
connection with medical treatment.
• The District of Columbia and 10 states -- Alaska, California,
Colorado, Maine, Massachusetts, Michigan, Nevada,
Oregon, Vermont and Washington -- have adopted the
most expansive laws legalizing marijuana for recreational
use.
• It is no wonder then that the legal marijuana market in the
U.S. is estimated to grow from $9.2 billion in 2017 to $47.3
billion in 2027.
• Another report from RBC Capital Markets showed that
American cannabis sales are quickly catching up to those
of beer and wine, and the market could be worth $47 billion
within a decade.
Www.CBDXFUND.COM

5. 5
Regulation
Cannabis Regulations
The regulatory environment is gradually shifting more
favorably on medical cannabis biopharmaceutical
cannabinoid at both federal and state level.
• For example, the H.R. 2, the Agriculture Improvement
Act of 2018, also known as the 2018 Farm Bill, H.R. 2
includes a provision that lift the ban on hemp,
authorize hemp production and research and amend
the Controlled Substances Act. See.
https://rules.house.gov/bill/115/hr-2.
• On December 12, 2018, U.S. Congress approved a
Bill to Make CBD Federally Legal. Passage of 2018
Farm Bill clarifies CBD legal status and lets U.S.
farmers grow hemp, but some regulatory questions
remain.
Www.CBDXFUND.COM

6. 6
Competition
Competition in Cannabis Industry
Right now there is no fund focused on rollup of existing high-
margin dispensaries California and across the U.S.
marketplace. In California for example, with 358 licensed
recreational marijuana stores, the state’s three licensing
authorities have issued over 5,000 commercial cannabis
licenses. So competition is not an issue now.
• There is excitement in the air as market sentiment among
investors and companies alike in the legal marijuana industry
grows more positive. Many states are promising to deliver new
markets, reducing risk exposure from the federal government
legally intervening. This situation is creating an inviting
paradigm for investors; stabilized business environments,
breakthroughs in Congress, and shifts in federal enforcement.
• Cannabis-related business such as our research and
development of cannabinoid, cannabidiol, endocannabinoids,
phytocannabinoids, and synthetic cannabinoids product
platform suitable for specific treatments, are gaining
acceptance in the eyes of the general public including the
recent pronouncements and conducts of the U.S. Food and
Drug Administration (FDA), showed that federal authorities are
not opposed to such research and development. Www.CBDXFUND.COM

7. 7
Opportunities For Cannabinoid Biosciences, Inc.
CBDZ is offering a Secured Convertible Note paying 8% annual interest. A
$1,000 Note is convertible into 80 shares of CBDZ Common Stock which is
currently being registered with the SEC under Reg. A+, to be sold at $10 per
share. CBDZ want to raise $125 million with Regulation A+ ($50 million) and
Regulation D 506(c) ($75 million).
• CBDZ is offering ordinary investors a quantified opportunity to get in at the ground floor of
Cannabis investment, at $2 for $1 of revenue.
• CBDZ will rollup 10 dispensaries with $54 million in annual revenue. These rollup will IPO on the
NASDAQ or NYSE and Canadian Securities Exchange (CSE). Once CBDZ successfully listed on
the NASDAQ, the $1,000 investment could would equal to paying $2 for $1 of sales, and would be
worth a lot more post-IPO because the post-IPO NASDAQ and NYSE pay $131-$215 for $1.
• The average Cannabis business trading on the market is selling at about $131-$215 times
revenue. This market cap to revenue only included those Cannabis businesses that have
revenue, since many of those currently trading have little or no revenue.
• Having worked on the rollups and consolidations that led to those public offering, we believe that
we could package a rollup that would provide investors with a chance to enter the cannabis
industry at the ground floor. For example, buying dispensaries and cultivation facilities at 2 time
revenue.
Our Potential
OPPORTUNITY TO GET IN ON THE GROUND FLOOR OF CANNABIS INVESTMENT
Www.CBDXFUND.COM

8. 8
Rollup & Consolidation
Investment Opportunity
Two of our business units are in flux and have
investment opportunities that we want to capitalize
upon immediately.
CBDZ want to raise $125 million with Regulation A+
($50 million), which is waiting for SEC qualification;
and Regulation D 506(c) ($75 million) through which
CBDZ is offering a Secured Convertible Note paying
8% annual interest with a minimum amount of $1,000
per unit.
* Each A $1,000 Note is convertible into 80 shares of
CBDZ Common Stock which is currently being
registered with the SEC under Reg. A+, to be sold at
$10 per share.
* Rollup and Consolidation: Investments into legal-
cannabis businesses and deriving value from
rollup/consolidation events that leads to IPO in US or
Canada; and
* Financial products in form of asset-backed loans,
business property mortgages and other financial
products to qualified individuals/businesses in the
legal-cannabis businesses.
Www.CBDXFUND.COM

9. 9
Rollup & Consolidation
Investment Opportunity
We need to raise $75 million to acquire ≥10 dispensaries which
we’ll rollup into our holding company and IPO on the NASDAQ or
New York Stock Exchange. All our targeted acquisitions are
profitable operations. We plan to keep 50% of the profits for
future growth, and pay 50% back to our investors as dividends.
 CBDZ provide investors with opportunity to invest in the
cannabis industry at the ground floor. For example, if an investor
wants to invest in the publicly traded cannabis businesses on the
stock market today, the investor would be paying $131-$215 for
every $1.00 of revenue on average.
 Investing with us would give the investors a better deal because
we’ll be acquiring cannabis businesses at close to 2:1 investment to
revenue. For example, with the 10 dispensaries identified, we’ll be
buying at less than $2.00 for every $1.00 of revenue.
We project that this rollup could be worth $4.6 billion on
the stock exchange once we have finished rollup and
consolidation of all the 10 dispensaries and cultivation
facilities. This valuation is based on the weighted average
multiple of X-sales and X-net profit of cannabis
businesses currently trading on the exchanges. Www.CBDXFUND.COM

10. 10
Cannabinoid Biosciences Market Opportunity
CBDZ has identified and
negotiated to purchase 10
dispensaries with cultivation
licenses in a multi-state rollup
that would be consolidated and
IPOed on the major exchanges in
Canada and the United States.
CBDZ has already filed a Reg A+
prospectus with the SEC for a
$50 million raise. We need to
raise $75 million via Regulation D
506 (c) via crowdfunding for the
acquisition.
Check out the chart below to see
why CBDZ actually offers
investors a quantified opportunity
to get in at the ground floor of
Cannabis investment, at $2 for
$1 of revenue.
Www.CBDXFUND.COM

11. 11
Cannabinoid Biosciences Market Opportunity

12. 12
5 Year Pro-Forma Summary
Compared to the currently NASDAQ/NYSE listed peers of ACB, CANN, CBDZ,
CGC, CRON, APHA and GWPH, a $54 million revenue with robust profitability
of $17 million would give CBDZ a market valuation north of $7.1 billion and
south of $2.2 billion.
2019 2020 2021 2022 2023
Revenue
Retail and Wholesales 54,237,238 63,544,375 74,448,621 87,224,040 102,191,728
Real Estate and Financial 372,320 1,703,880 3,420,480 4,593,480 5,383,480
Industry Turnkey Solutions 294,000 3,243,600 13,149,321 17,318,186 22,068,824
Compliance Solutions 56,000 1,329,000 4,212,000 5,122,000 7,642,000
Industry Rollup 0 0 0 60,000,000
Total Gross Revenue (USD) 54,959,558 69,820,855 95,230,422 114,257,706 197,286,032
Net profit $17,091,402 $20,024,295 $23,460,474 $27,486,303 $32,202,966
Dividend Distributions 8,545,701 10,012,148 11,730,237 13,743,151 16,101,483
Reinvestments 8,545,701 10,012,148 11,730,237 13,743,151 16,101,483
Projected Market Capitalization $4.68 Billion $5.48 Billion $6.42 Billion $7.52 Billion $8.82 Billion
Visit us at: Www.CBDXFUND.COM

13. The following summarizes the key
terms of the Secured Convertible
Notes and the private placement.
Please refer to the relevant
sections of the PPM and related
documents, including the
Company‛s articles of
incorporation (“Articles”) for
more complete details about the
Secured Convertible Notes and the
private placement.
Visit us at: Www.CBDXFUND.COM

14. Issuer Cannabinoid Biosciences, Inc.
Security Secured Convertible Note into Common Stock
Discount 0%
Interest Rate 8% Per Annum (payable fifteen days after the end of the year)
Maturity December 31st 2023
Valuation Cap N/A
Floor N/A
Minimum Subscription $1,000 per investor
Maximum Subscription $75 million per investor
Initial Closing Min. of $10K before 03/07/2020
Additional Closings One or more; up to a total of $75 million
Use of Proceeds Rollup Cannabis and fund growth across US
Dividend Declarations Dividend payment in year 4, subject to Board approval
Liquidity Event Sale of company or listing on a major stock exchange
Mandatory Conversion Converts to Shares of Common Stock
Resale Restrictions No resale permitted within 12 months & Board approval
Voting Rights Per Cannabinoid Biosciences Inc. Articles of Incorporation and By Laws
Registrar and Transfer Agent FundAmerica (VStock Transfer)
Escrow Company Prime Trust
Corporate Bank Bank of America
Legal Counsel Law Office of Azuka L Uzoh
ISIN / CUSIP To be issued
Governing Law Laws of California Visit us at: Www.CBDXFUND.COM

15. A California Based
Biopharmaceutical
company
Thank You
Www.CBDXFUND.COM
Frank I Igwealor, CPA, JD, MBA, CMA, CFM, MSRM
Sr. Vice President and CFO
This Cannabinoid Biosciences presentation contains
certain forward-looking statements that are subject to
known and unknown risks and uncertainties that
could cause actual results to differ materially from
those expressed or implied by such statements.
Such risks and uncertainties include, but are not
limited to the Risk Factors noted in the Company’s
filings with the Securities and Exchange Commission.
The Company undertakes no obligations to update
any forward-looking statements, whether as a result
of new information, future events or otherwise.